Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

S Kümmerl1, J Krocker2, A Kohls3, G-P Breitbach4, G Morack5, M Budner6, J-U Blohmer1 and D Elling2

1Department of Gynecology/Obstetrics, University Medicine Berlin, Charité Campus Mitte, Schumannstr. 20/21, Berlin 10117, Germany; 2Krankenhaus Lichtenberg, Klinik für Frauenheilkunde, Fanningerstr. 32, Berlin 10365, Germany; 3Evangelisches Krankenhaus Ludwigsfeld-Teltow, Ludwigsfelder GmbH, Albert-Schweitzer-Str. 42-44, Ludwigsfeld 14974, Germany; 4Städtisches Klinikum Neunkirchen GmbH, Neunkirchen GmbH, Brunnenstr. 20, Neunkirchen/ Saar D-66538, Germany; 5Helios Klinikum Berlin-Buch, Wittbergr. 50, Berlin 13125, Germany; 6Humaine-Klinikum Bad Saarow, Pieskowerstr. 33, Bad Saarow-Pieskow 15526, Germany

We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer. Randomised patients (n = 216) received DD or conventional-schedule (CS) chemotherapy. Dose-dense regimen patients (n = 108) received epirubicin 90 mg m⁻² plus paclitaxel 175 mg m⁻² in four 14-day cycles, then cyclophosphamide 600 mg m⁻², methotrexate 40 mg m⁻², and fluorouracil 600 mg m⁻² (CMF 600/40/600) in three 14-day cycles, plus filgrastim 5 μg kg⁻¹ as growth support in every cycle. Conventional-schedule regimen patients (n = 108) received epirubicin 90 mg m⁻² plus cyclophosphamide 600 mg m⁻² in four 21-day cycles, then CMF 600/40/600 in three 21-day cycles, plus filgrastim if required. After a median follow-up of 38.4 months, 71 patients (33%) relapsed or died; DD, 33 patients (15 deaths); CS, 38 patients (22 deaths). Dose dense showed a trend for improved disease-free survival (DFS) and overall survival (OS). Four-year rates of DFS and OS were 64% and 85% for DD, and 58% and 75% for CS. All seven cycles were administered to 208 patients (96%). Rates of cycle delay, discontinuation, dose reduction, and adverse events were similar in both groups. Dose-dense sequential chemotherapy with epirubicin/paclitaxel then CMF, supported by filgrastim, is safe and improves survival for patients with node-positive breast cancer.

British Journal of Cancer (2006) 94, 1237 – 1244. doi:10.1038/sj.bjc.6603085 www.bjcancer.com
Published online 11 April 2006 © 2006 Cancer Research UK

Keywords: breast cancer; clinical trial; dose dense; epirubicin; filgrastim; paclitaxel

Dose-dense (DD) adjuvant chemotherapy regimens for node-positive breast cancer limit the opportunity for the regrowth of cancer cells between chemotherapy cycles and improve disease-free survival (DFS) and overall survival (OS) compared with conventional treatment regimens (Wood et al, 1994; Budman et al, 1998; Citron et al, 2003). For breast cancer tumours that are resistant to conventional therapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), anthracyclines (e.g., doxorubicin or epirubicin) and taxanes (e.g., paclitaxel or docetaxel) are active and increase survival for many patients (Glück, 2001).

Anthracyclines and taxanes have different mechanisms of action, little overlap in haemotoxicity, and limited crossresistance (Glück, 2001). In clinical studies, sequential administration of doxorubicin followed by CMF and paclitaxel in combination with doxorubicin improved survival compared to CMF alone (Bonadonna, 1996). Epirubicin provides comparable response rates to those of doxorubicin, with reduced cardiotoxicity at equivalent doses (Lück et al, 1996; Glück, 2001). The survival advantages of epirubicin have been confirmed in several clinical trials, including 7- and 10-year studies (Early Breast Cancer Trialists’ Collaborative Group, 1998; Levine et al, 1998; Fumoleau et al, 2003a,b; Poole et al, 2003; Bonneterre et al, 2005). Recent evidence suggests that adding taxanes to anthracycline regimens may further improve patient survival (Henderson et al, 2003; Roché et al, 2004; Martin et al, 2005).

Using anthracyclines and taxanes in a DD schedule of sequential combination chemotherapy has been shown to confer a survival benefit compared to conventional regimens (Glück, 2001; Citron et al, 2003; Möbus et al, 2004). However, DD therapy carries an increased risk of febrile neutropenia, a potentially fatal complication for up to 10% of patients. Neutropenia also may increase the risk and cost of treatment and result in dose reduction or delay of planned chemotherapy (Oz et al, 2000). Studies of dose-intense regimens demonstrate that delay in the administration of planned chemotherapy or reduction of doses may be associated with decreased DFS and OS (Bonadonna et al, 1995; Budman et al, 1998). Growth factor support in DD chemotherapy regimens can reduce the incidence of neutropenic complications, thereby facilitating the administration of a high percentage of chemotherapy doses as planned (Bonadonna, 1996). Because delivery of planned doses of chemotherapy is associated with improved survival, DD regimens often include growth factor support (Bonadonna, 1996; Link et al, 2001; Citron et al, 2003; Möbus et al, 2004).

Our prospective, randomised multicentre clinical study compares the rates of DFS and OS associated with two adjuvant...
treatment regimens for primary breast cancer in patients with >4 positive lymph nodes: epirubicin and paclitaxel followed sequentially by CMF in a DD schedule, vs a standard regimen of epirubicin and cyclophosphamide followed sequentially by CMF in a conventional schedule. The feasibility and tolerability of the regimens are also compared. Growth factor support was provided in all cycles to all patients in the DD group, and as needed to patients in the conventional-schedule (CS) group. Early feasibility and toxicity data have been reported previously (Elling et al, 2000); this interim report describes DFS, OS, safety, feasibility, and tolerability after an average of 38.4 months of follow-up.

PATIENTS AND METHODS

Study population

This study was conducted in accordance with the ethical principles defined in the Declaration of Helsinki of the World Medical Association. The protocol was approved by each institution’s ethics committee, and each enrolled patient provided written informed consent. A total of 231 female patients were enrolled in the study at 30 centres in Germany between July 1996 and December 2000. Patients had primary resected, histologically confirmed breast cancer, stage I, II, or III (Sobin et al, 1997). Surgical procedures, performed ≤15 days before randomisation, included R0 resection and axillary extirpation (levels I to II obligatory, or level III depending on the clinical situation). Patients had >4 positive axillary lymph nodes, no distant metastases, an Eastern Cooperative Oncology Group (ECOG) performance status <2, adequate organ function, and no previous chemotherapy or radiotherapy. Exclusion criteria included leucocytes <3.5 x 10^9/l or platelets <100 x 10^9/l. One patient with an ECOG performance status of 3 was admitted to the study in violation of the protocol; this patient was included in the analysis.

Study design

This multicentre, randomised, open-label Phase 3 adjuvant therapy optimisation study evaluates a DD sequential chemotherapy regimen administered after mastectomy or breast-conserving surgery. The primary end point of the study was the rate of DFS of patients receiving the two sequential regimens. The secondary end points were the rates of OS in the two groups, the incidence of chemotherapy postponement or dose reduction, and the safety and tolerability of the regimen. The study also examined factors that may affect DFS, including hormone receptor status, number of positive lymph nodes, tumour status, malignancy grade, age, haemoglobin values, and delays in chemotherapy administration.

Eligible patients were randomised in permuted blocks, stratified by centre, to one of the two chemotherapy treatment groups (DD-schedule group or CS group) using a computer-generated randomisation list (Figure 1). The DD-schedule group received treatment with four cycles of epirubicin and paclitaxel at 14-day intervals, followed by three cycles of CMF at 21-day intervals. All patients in the DD-schedule group received filgrastim in each cycle, administered at a dose of 5 μg/kg day^−1 beginning on day 5 and continuing until either day 13 or leucocyte counts reached >10 x 10^9/l. The CS group received a conventional sequential regimen: four cycles of epirubicin and cyclophosphamide at 21-day intervals followed by three cycles of CMF at 21-day intervals. Patients in the CS group were treated with filgrastim in subsequent cycles if they experienced any of the following events during a cycle: absolute neutrophil count (ANC) <0.5 x 10^9/l for more than 2 days, a fever of unknown origin (>38.5°C), infection, or the interval between cycles of chemotherapy prolonged by more than 3 days because of ANC ≤2.5 x 10^9/l. Assigned chemotherapy regimens were initiated no later than 21 days after surgery (tumour resection or mastectomy) if patients met the study entry criteria. Patients were required to exhibit haematologic recovery (ANC ≥1.0 x 10^9/l and platelets ≥50 x 10^9/l) on the scheduled start day for the next cycle before receiving chemotherapy. The initial postponement was 3 days, followed by a repeated measurement and another postponement, if required, of 3 to 4 days, if haematologic recovery had not occurred.

The treatment phase of the study ended when patients achieved haematologic recovery after the last administration of chemotherapy in accordance with protocol. Patients were followed for up to 5 years after inclusion in the study with regularly scheduled visits.

Treatment procedures

At baseline and at the end of the study, patients underwent physical examinations, including the measurement of baseline characteristics, disease staging, and performance status, as well as thoracic radiographs, mammography of the contralateral breast, and abdominal sonography. Left ventricular ejection fraction was measured by electrocardiogram or echocardiogram. Other assessments were performed at the investigator’s discretion. Complete blood counts (CBC) and other appropriate laboratory tests were also performed. A CBC was obtained twice weekly during treatment. During the period of expected postchemotherapy neutrophil count nadir, a CBC was taken every 2 days. Electrolytes, creatinine, and C-reactive protein measurements were taken weekly.

Each group received two sequences of chemotherapy. The DD-schedule group began the first sequence of epirubicin 90 mg m^−2 by short intravenous (i.v.) infusion, followed by a 3-h i.v. infusion of paclitaxel 175 mg m^−2 on day 1, repeated for four cycles at a planned interval of 14 days. In the second sequence of treatment, DD-schedule group patients received three cycles of cyclophosphamide 600 mg m^−2, methotrexate 40 mg m^−2, and 5-fluorouracil 600 mg m^−2 (CMF 600/40/600) by short i.v. infusion at a planned interval of 14 days. The DD-schedule group also received filgrastim 5 μg/kg day^−1 in each cycle during both sequences of chemotherapy. For the CS group, the first chemotherapy sequence consisted of a short i.v. infusion of epirubicin 90 mg m^−2 and cyclophosphamide 600 mg m^−2, repeated for four cycles at a planned interval of 21 days. In the second sequence, the CS group received three cycles of CMF 600/40/600 by short i.v. infusion at a planned interval of 21 days. Patients in the CS group could have received filgrastim if required.

Patients receiving paclitaxel received appropriate premedication before administration of paclitaxel. Supportive medications were administered at the investigator’s discretion. Patients who experienced febrile neutropenia were treated according to the standard operating procedures of each centre. Patients with a fever ≥38°C who had not received blood products received antibiotic therapy. Empirical antibiotic therapy in patients with febrile neutropenia without a positive blood culture was discontinued after the patient had been afebrile for 72 h, provided the neutropenia was resolved. Platelet transfusions were given when a patient’s platelet count fell to 15 x 10^9/l or below. Erythrocyte concentrates were given in accordance with standard practice at the investigator’s institution. All supportive measures, treatments for infection, transfusions, and administrations of erythrocyte concentrate were documented.

All patients with positive oestrogen or progesterone receptor status received tamoxifen 20 mg day^−1 for 5 years. All patients who had undergone breast-conserving surgery received adjuvant radiotherapy (40–50 Gy) on completion of the chemotherapy.

Statistical analysis

DFS and OS measurements The trial was designed to detect a difference of 15% (60% vs 75%) in the primary end point of DFS after 5 years, with a risk of type 1 error of 5% (one-sided) and...
a power of approximately 80%, based on the planned sample size of 121 patients in each treatment group. Kaplan–Meier curves were used to analyse DFS and OS. No interim analyses were planned or performed, so multiple analyses were not considered. The randomised and prognostic groups were compared using the log-rank test (Peto et al., 1977), and hazard ratios were provided with 95% confidence limits. Unless specifically designated as one-sided, all \( P \)-values are two-sided. Except for the primary end point, all analyses and statistical tests were performed as descriptive or exploratory.

Feasibility, safety, and tolerability The feasibility of DD chemotherapy in a sequential therapy regimen was measured as the percent of evaluable chemotherapy cycles that were delayed from the planned schedule and the percent of postponed cycles caused by a delay in haematologic recovery. Safety and tolerability were defined in terms of adverse events during treatment and follow-up.

Data sets All data for eligible patients were included in the survival analysis and analysed on the basis of intention-to-treat. All data for patients who received at least one chemotherapy cycle were included in the safety and tolerability analysis, except for two patients for whom haemotoxicity data were not available. Descriptive or exploratory analyses were performed for the results included in this report.

RESULTS A total of 231 women aged 26 to 72 years (mean age, 53 years, standard deviation (s.d.) 10 years), 60% of whom were postmenopausal, enrolled at 30 centres between July 1996 and December 2000. They were randomly assigned to one of two schedule groups: 116 patients to DD therapy and 115 patients to a CS regimen. A total of 15 patients were excluded because of ineligibility. In total, 10 patients were ineligible (five in each
group) because of a T4 tumour (Sobin et al, 1997). The remaining five patients were ineligible for the following reasons: existing metastasis, history of malignant melanoma, previous chemotherapy or radiotherapy, tumour activity with uncertain breast cancer histology, and erroneous chemotherapy administration. The remaining 216 patients entered the study (108 in each treatment group). One patient refused further treatment after cycle 1 (Figure 1).

Of the 231 patients enrolled, 216 (94%) were evaluated for efficacy and safety. Patient and disease characteristics in each treatment group are summarised in Tables 1 and 2. While the original study design excluded patients with >9 positive lymph nodes, the protocol was subsequently amended to permit 48 patients with >9 lymph nodes to be included in the study (26 (24%) in the DD-schedule group, 22 (20%) in the CS group).

Disease-free survival
At a median follow-up of 38.4 months, 71 patients (33%) experienced a first event of relapse or death, including 33 events (31%) in the DD-schedule group and 38 events (35%) in the CS group.

The DFS rate after 2 years was 81% (95% confidence limits (CL), 74–89%) in the DD-schedule group and 72% (64–81%) in the CS group. After 4 years, the DFS rate was 64% (55–76%) in the DD-schedule group and 58% (48–70%) in the CS group. There was a trend for DFS in favour of the DD-schedule group, although the difference was not significant (log-rank test, one-sided trend for DFS in favour of the DD-schedule group, although the difference was not significant (log-rank test, one-sided P = 0.12) (Figure 2). The hazard ratio, with the DD-schedule group as reference, was 1.32 (0.82 to 2.11) at the time of this analysis. The most common site of disease relapse was bone metastasis (31% of cases), followed by metastasis at local sites, including chest wall, thoracic wall, and axillary and infraclavicular lymph nodes (23%).

Overall survival
At a median follow-up duration of 38.4 months, 37 (17%) of 216 patients have died, including 15 patients (14%) in the DD-schedule group and 22 (20%) in the CS group (Figure 3). The OS rate after 2 years was 94% (89–99%) in the DD-schedule group and 92% (87–97%) in the CS group. After 4 years, the OS rate was 85% (78–94%) in the DD-schedule group and 75% (66–85%) in the CS group (Figure 3). The hazard ratio, with the DD-schedule group as reference, was 1.76 (CL 0.91–3.38; log-rank test, two-sided P = 0.092), suggesting a possible increased risk of death for patients receiving the CS regimen.

Feasibility (dose reduction or cycle delay)
A total of 1480 cycles of chemotherapy were administered (735 in the DD-schedule group and 745 in the CS group), and 96% of patients in both groups received all seven cycles. The mean (s.d.) cycle length was 14.7 days (3.5) for the DD-schedule group and 21.3 days (1.9) for the CS group.

Commencement of chemotherapy was delayed by more than 1 day in only 10% of DD cycles and 7% of CS cycles. Cycle delays because of delayed haematologic recovery were slightly more common in the DD group (12 cycles, 17%) than in the CS group (six cycles, 12%). Administrative reasons and infection caused most postponements in the other 85% of delayed cycles. No reasons for delayed cycles were reported for two patients.

Doses were reduced in 14 of 1477 evaluable cycles (1%), with no notable differences between groups. (Three cycles were not evaluable because data about dose reductions and delays were missing.) Dose reduction resulting from haematologic toxicity occurred in only one cycle, in the DD-schedule group. In most other cases, doses were reduced because of weight loss resulting in decreased body surface area.

Safety and tolerability
The safety and tolerability of the two regimens were similar, as assessed by discontinuation and interruption of therapy, laboratory values, and adverse events. The rate of discontinuation was the same (4%) in both treatment groups. One patient in the CS group died during therapy, and one patient in the DD-schedule group received a delayed cycle 8 due to an infection (Figures 1 and 3). There were no dose reductions in the DD-schedule group because of castrate or premenopausal levels. However, two patients in the CS group had dose reductions due to haematologic toxicity (12 cycles, 17%) compared with one patient in the DD-schedule group (six cycles, 12%).

Table 1 Patient characteristics in each treatment group

|                          | Dose-dense-schedule group | Conventional-schedule group | Total |
|--------------------------|---------------------------|-----------------------------|-------|
| Patients randomised (n)  | 116                       | 115                         | 231   |
| Not eligible (n)         | 8                         | 7                           | 15    |
| Evaluated for efficacy (n) | 108                       | 108                         | 216   |
| Age (years) (mean (sd))a | 53.3 (9.8)                 | 52.5 (9.8)                  | 52.9 (9.8) |
| <30 years (n (%))        | 2 (2%)                    | 0 (0%)                      | 2 (1%) |
| 30–39 years (n (%))      | 10 (10%)                  | 14 (13%)                    | 24 (11%) |
| 40–49 years (n (%))      | 19 (18%)                  | 30 (28%)                    | 49 (23%) |
| 50–59 years (n (%))      | 48 (46%)                  | 36 (34%)                    | 84 (40%) |
| 60–69 years (n (%))      | 23 (22%)                  | 25 (23%)                    | 48 (23%) |
| >70 years of age         | 2 (2%)                    | 2 (2%)                      | 4 (2%) |
| Menopause status at diagnosisb |                       |                             |       |
| Premenopausal (n (%))    | 42 (39%)                  | 44 (41%)                    | 86 (40%) |
| Postmenopausal (n (%))   | 65 (61%)                  | 63 (59%)                    | 128 (60%) |
| Activity status at diagnosisb (Oken et al, 1982) | | | |
| ECOG 0 (n (%))           | 89 (86%)                  | 87 (84%)                    | 176 (85%) |
| ECOG 1 (n (%))           | 12 (12%)                  | 16 (15%)                    | 28 (14%) |
| ECOG 2 (n (%))           | 1 (1%)                    | 1 (1%)                      | 2 (1%) |
| ECOG 3 (n (%))           | 1 (1%)                    | 0 (0%)                      | 1 (0%) |
| Patients undergoing surgery (n) | 108                       | 108                         | 216   |
| Breast conserving (n (%))| 42 (39%)                  | 46 (43%)                    | 88 (41%) |
| Mastectomy (n (%))       | 66 (61%)                  | 62 (57%)                    | 128 (59%) |

ECOG = Eastern Cooperative Oncology Group. aNo date of birth given for five patients. bNo menopause status given for two patients. cNo activity given for nine patients.

© 2006 Cancer Research UK

British Journal of Cancer (2006) 94(9), 1237 – 1244
group refused further treatment after receiving first-cycle therapy. Two patients (2%) in the DD-schedule group and one patient (1%) in the CS group discontinued because of toxicity, including acute hypersensitivity reactions, febrile neutropenia, and fatigue. Three patients (one in the DD-schedule group, two in the CS group) discontinued for other reasons, including withdrawal of consent, uncontrolled diabetes, and infection of a breast wound.

Of 1477 evaluable chemotherapy cycles administered, nine infusions (<1%) had interruptions from 10 min to 24 h (733 cycles in the DD-schedule group, 744 cycles in the CS group). One patient in the DD-schedule group experienced an acute hypersensitivity reaction to paclitaxel, and therapy was discontinued. Reasons for interruption included burning sensations at the infusion site, paravasation, and a defective container.

### Haematologic Toxicity
Filgrastim was administered to all patients in the DD-schedule group in every cycle. In the CS group, filgrastim was administered in 111 of 745 cycles (14.9%), on an as-needed basis. Leukopenia and neutropenia occurred in both treatment groups at similar rates (Table 3). No patients experienced grade 4 anaemia or grade 4 thrombocytopenia. Grade 3 anaemia and grade 3 thrombocytopenia were rare in both groups. Analysis of haematologic toxicity on the basis of cycles yielded similar results.

### Nonhaematologic Toxicity
The most frequently reported non-haematologic adverse events were alopecia, nausea, and vomiting (Table 3). Fatigue, mucositis, bone pain, and peripheral nervous system (PNS) toxicity were also frequently reported. The incidence of nonhaematologic toxicity was similar in both treatment groups, except for one adverse event commonly associated with paclitaxel and two adverse events commonly associated with filgrastim. Events that occurred more often in the DD-schedule group than the CS group include PNS toxicity (47% vs 11%), bone pain (44% vs 10%), and peripheral neuropathy (20% vs 5%).

---

**Table 2** Disease characteristics in each treatment group

|                      | Dose-dense-schedule group | Conventional-schedule group |
|----------------------|---------------------------|-----------------------------|
|                      | Age ≤ 50 years (n = 34)   | Age > 50 years (n = 70)     |
| Oestrogen hormone receptor statusb (n) |                      |                             |
| Positive (n (%))     | 22 (65%)                  | 50 (71%)                   |
| Borderline or threshold (n (%)) | 1 (3%)                  | 5 (7%)                     |
| Negative (n (%))     | 10 (29%)                  | 14 (20%)                   |
| Not determined (n (%)) | 1 (3%)                  | 1 (1%)                     |
| Histopathological gradec (n) |                      |                             |
| G1 (n (%))           | 1 (3%)                    | 5 (7%)                     |
| G2 (n (%))           | 15 (44%)                  | 35 (51%)                   |
| G3 (n (%))           | 18 (53%)                  | 29 (42%)                   |
| Tumour stage (n)     | 34                        | 70                         |
| T1 (n (%))           | 8 (24%)                   | 24 (34%)                   |
| T2 (n (%))           | 20 (59%)                  | 33 (47%)                   |
| T3 (n (%))           | 6 (18%)                   | 13 (19%)                   |
| T4 (n (%))           | 0 (0%)                    | 0 (0%)                     |
| TX (n (%))           | 0 (0%)                    | 0 (0%)                     |
| Nodal stage (n)      | 34                        | 70                         |
| N1 (n (%))           | 29 (85%)                  | 63 (90%)                   |
| N2 (n (%))           | 5 (15%)                   | 6 (9%)                     |
| N3 (n (%))           | 0 (0%)                    | 1 (1%)                     |
| Lymph node status (n) | 34                      | 70                         |
| 4–9 involved nodes (n (%)) | 27 (79%)               | 51 (73%)                   |
| >9 involved nodes (n (%)) | 7 (21%)               | 19 (27%)                   |

*No date of birth given for five patients. bNo hormone receptor status given for one patient. cNo malignancy grades given for three patients.

---

**Figure 2** Disease-free survival.

**Figure 3** Overall survival.
Other potential predictors of survival

The effects on DFS of hormone receptor status, menopausal status, number of positive lymph nodes, primary tumour status (T-stage), malignancy grade, age, haemoglobin value, and delays in chemotherapy cycles were also analysed.

Oestrogen hormone receptor status (Figure 4) Negative or borderline hormone receptor status had a negative effect on DFS that was statistically significant (two-sided \( P = 0.0044 \)). After 2 years, patients with a negative or borderline hormone receptor status had a 62% (50–77%) DFS rate compared with an 82% (76–89%) DFS rate for hormone-receptor-positive patients. After 4 years, the DFS rate for hormone receptor-negative or borderline patients was 48% (35–66%) compared with a 66% (57–75%) DFS rate for hormone-receptor-positive patients. While the data in Figure 4 suggest that patients with negative hormone receptor status profit most from DD therapy, the small sample size warrants a cautious interpretation of this analysis.

Menopausal status Menopausal status had no significant effect on DFS in this study.

Number of positive lymph nodes (Figure 5) The prognostic utility of axillary lymph node status in primary breast cancer was confirmed in this study (two-sided \( P = 0.017 \)). After 2 years, patients with \( > 9 \) positive lymph nodes had a DFS rate of 68% (56–83%) compared with 79% (73 to 86%) for patients with 4 to 9 positive lymph nodes. After 4 years, patients with \( > 9 \) positive lymph nodes had a DFS rate of 48% (35 to 65%) compared with 66% (57 to 75%) for patients with four to nine positive lymph nodes. Patients in the DD-schedule group who had \( > 9 \) positive lymph nodes had a survival advantage compared to patients with \( > 9 \) positive nodes in the CS group (Figure 5). As with hormone receptor status, this subgroup analysis should be interpreted with caution because of the small sample size.

Tumour status (T-stage) The stage of the tumour at the time of diagnosis was also a predictor of DFS, with tumours \( > 5 \) cm showing a clearly less favourable prognosis (two-sided \( P = 0.0057 \)). At 2 years, patients with stage T1 tumours had an 85% DFS rate (76–94%) compared with 78% (70–86%) for patients with stage T2 tumours and 64% (50–82%) for patients with stage T3 tumours. After 4 years, DFS was 76% (64–90%) for patients with stage T1 tumours, 62% (52–73%) for patients with stage T2 tumours, and 40% (26–62%) with stage T3 tumours.

Malignancy grade Malignancy grade was not as strong a predictor of DFS as tumour stage, but differences between malignancy

---

**Table 3** Haematologic and nonhaematologic toxicity: highest WHO grade for each patient

|                      | Toxicity                      | Conventional-schedule group |
|----------------------|-------------------------------|-----------------------------|
|                      | Dose-dense-schedule group     | WHO grade\(^a\) (n (%))     | Conventional-schedule group |
|                      | \( n \) | 0 | 1 or 2 | 3 | 4 | \( n \) | 0 | 1 or 2 | 3 | 4 |
| **Haematologic**     |                      |                          |                      |                      |                          |                      |                          |                      |                      |                          |                      |                          |
| Leukopenia           | 108 | 10 (9%) | 50 (46%) | 40 (37%) | 8 (7%) | 107 | 8 (7%) | 47 (44%) | 46 (43%) | 6 (6%) |
| Neutropenia          | 77  | 9 (12%) | 20 (26%) | 26 (34%) | 22 (29%) | 82  | 12 (15%) | 17 (21%) | 23 (28%) | 30 (37%) |
| Thrombocytopenia     | 107 | 82 (77%) | 22 (21%) | 3 (3%) | 0 | 107 | 97 (91%) | 10 (10%) | 0 | 0 |
| Anaemia              | 108 | 14 (13%) | 90 (83%) | 4 (4%) | 0 | 107 | 42 (39%) | 64 (60%) | 1 (1%) | 0 |
| **Nonhaematologic** |                      |                          |                      |                      |                          |                      |                          |                      |                      |                          |                      |                          |
| Alopecia             | 108 | 6 (6%) | 16 (15%) | 86 (80%) | 0 | 107 | 4 (4%) | 14 (13%) | 89 (83%) | 0 |
| Nausea/vomiting      | 108 | 14 (13%) | 87 (81%) | 7 (6%) | 0 | 107 | 10 (9%) | 85 (79%) | 11 (10%) | 1 (1%) |
| Fatigue              | 108 | 42 (39%) | 58 (54%) | 8 (7%) | 0 | 107 | 52 (48%) | 52 (49%) | 3 (3%) | 0 |
| Mucositis            | 108 | 57 (53%) | 42 (39%) | 9 (8%) | 0 | 107 | 60 (56%) | 45 (42%) | 2 (2%) | 0 |
| Bone pain            | 108 | 60 (56%) | 43 (40%) | 5 (5%) | 0 | 107 | 82 (76%) | 22 (21%) | 2 (2%) | 1 (1%) |
| PNS toxicity         | 108 | 57 (53%) | 50 (46%) | 1 (1%) | 0 | 107 | 95 (88%) | 11 (10%) | 1 (1%) | 0 |
| Arthralgia/myalgia   | 108 | 84 (78%) | 20 (19%) | 4 (4%) | 0 | 107 | 91 (84%) | 16 (15%) | 0 | 0 |

PNS = peripheral nervous system; WHO = World Health Organization. \(^a\)Because of rounding, percentages may not total 100%.

---

**Figure 4** Disease-free survival by treatment group and oestrogen hormone receptor status.

**Figure 5** Disease-free survival by treatment group and nodal status.
grades were statistically significant (two-sided $P = 0.046$). After 2 years, patients with grade G1 or G2 had a DFS rate of 81% (74–89%) compared with 71% (62–81%) for grade G3 malignancies. After 4 years, patients with G1 or G2 malignancies had a DFS rate of 67% (56–78%) compared with 53% (43–66%) for patients with G3 malignancies (Figure 6).

**Age** As expected, there was a trend toward a less favourable outcome for younger patients, although the trend was not statistically significant. After 2 years, patients ≥50 years of age had a DFS of 80% (73–87%) compared with 71% (62 to 83%) for patients <50 years. After 4 years, results were similar; patients ≥50 years of age had a DFS of 63% (54–73%) compared with 57% (45–73%) for patients <50 years.

**Haemoglobin values** It has been proposed that a low haemoglobin value is associated with a less favourable prognosis. Interim results from this study do not support this hypothesis, either for a baseline haemoglobin <12 g dl$^{-1}$ or for a haemoglobin nadir <11 g dl$^{-1}$ during therapy (data not shown).

**Chemotherapy cycle delay** Although several studies have shown that a delay in administration of chemotherapy cycles negatively affects DFS, that effect was not significant in this study. The small number of cycle delays ≥2 days (eight in each treatment group) warrants caution in interpreting these results.

**DISCUSSION**

Advances in treatment strategies for node-positive breast cancer include the identification of the chemotherapy agents (including epirubicin and paclitaxel) that are active against tumours resistant to CMF therapy. This study demonstrates that combining epirubicin and paclitaxel followed by CMF in DD adjuvant chemotherapy is feasible, safe, and tolerable for most patients, and that this combination appears to improve OS and DFS in node-positive breast cancer compared with conventional treatment schedules using epirubicin and cyclophosphamide. The use of filgrastim support to prevent neutropenia enhances the safety and tolerability of this regimen. It may also contribute to the rarity of cycle delays in chemotherapy administration in this study.

Discontinuations, cycle delays, and dose reductions were few, which may reflect the lower toxicity of epirubicin and the myeloprotective effects of filgrastim. Peripheral neuropathy, bone pain, and arthralgia/myalgia, which were more common in the DD treatment group, are associated with both paclitaxel and filgrastim; the design of this study does not permit a direct association of these side effects with a single drug.

The benefit of DD therapy for patients with four or more positive axillary nodes is consistent with that seen in Cancer and Leukaemia Group B (CALGB) study 8541 (Wood et al, 1994), but the treatment regimen used in our study resulted in somewhat higher DFS rates; in CALGB study 8541 of treatment with cyclophosphamide, doxorubicin, and 5-fluorouracil, patients with $\geq 4$ positive nodes who received high-dose therapy had a DFS rate of 67% after 3 years compared with 62% for a DD therapy schedule and 46% for low-dose therapy. In comparison, 4-year DFS rates in our study were 64% for the DD-schedule group and 58% for the CS group. In CALGB study 8541, patients with $\geq 10$ positive nodes fared worst, but still did better with DD therapy than with low-dose therapy (44% DFS rate after 3 years with high-dose or DD therapy vs 28% for low-dose therapy) (Wood et al, 1994). The treatment regimens in our study resulted in a DFS rate of 48% (35–65%) for patients with $\geq 10$ positive nodes after 4 years, a modest improvement over the CALGB 8541 results.

Results of this study are similar to those reported in the German AGO study, in which estimated 3-year DFS rates were 80% (DD group) and 70% (CS group) for patients with $\geq 4$ positive lymph nodes receiving regimens of epirubicin, paclitaxel, and cyclophosphamide. (Möbus et al, 2004). OS rates in the AGO study were also comparable to those observed in this study (Möbus et al, 2004).

In our study, patients with negative hormone receptor status or $>9$ positive lymph nodes, who have a generally poorer prognosis, benefited from the DD treatment schedule (Figures 4 and 5). At the same time, because patients with $>9$ lymph nodes fared worse than patients with $\leq 9$ positive lymph nodes, the inclusion of these patients in the study reduced the OS and the DFS of the total patient population. The potential effect of the number of lymph nodes on survival can be seen by comparing the population in our study with that in the C9741 study (Citron et al, 2003). In C9741, 59% of the patients had one to three positive lymph nodes, while all patients in our study had at least four positive lymph nodes. Only 12% of patients in the C9741 study had 10 or more positive nodes compared with 22% of the patients in our study. The 4-year DFS in the C9741 study was 82% for patients receiving DD therapy compared with 64% for patients receiving DD treatment in our study.

In the C9741 study, the DD regimen significantly reduced the incidence of contralateral breast cancer (0.3 vs 1.5%, $P = 0.0004$) (Citron et al, 2003); our study did not confirm that finding, as three patients in each treatment group had contralateral breast cancer. While recent studies of epirubicin-based regimens have shown higher OS and DFS rates than those reported here (Citron et al, 2003; Henderson et al, 2003; Poole et al, 2003), our study is unique in its demonstration of survival benefits for patients with $\geq 4$ positive axillary lymph nodes.

The results of this prospective, randomised multicentre study provide further evidence that a DD therapy combining anthracyclines with paclitaxel or cyclophosphamide, supported by filgrastim from the first cycle of chemotherapy, can prolong OS and DFS in high-risk patients.

As this is an interim report of a relatively small patient population, caution must be exercised in the interpretation of these results. Fewer patients were originally enrolled than originally planned, potentially reducing the statistical power of the study. Additionally, because of logistic concerns, this regimen may not be feasible in all countries or hospitals. Finally, the risk of leukaemia or myelodysplasia consequent to growth factor therapy must be considered, even though this risk appears to be low and not limited to DD regimens. Hudis et al reported an incidence of leukaemia or myelodysplasia $\leq 1\%$ in DD and conventional treatment groups after a median 6.5 years of follow-up in the C9741 study. (Ozer et al, 2000; Hudis et al, 2005). Analysis of mature data at a mean follow-up of 5 years will shed additional light on the selection of an optimum therapy.
ACKNOWLEDGEMENTS

Financial and logistic support for this study was provided by Amgen Inc., Pfizer, and Bristol-Myers Squibb. Dr Axel Hinke and Ms Karin Burock provided statistical analysis, and Joan O’Byrne and Sue Hudson provided medical writing assistance in the preparation of this manuscript.

REFERENCES

Bonadonna G (1996) Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute. Eur J Cancer 32A: 209 – 214

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901 – 906

Bonnetterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namen M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23: 2686 – 2693

Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90: 1205 – 1211

Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431 – 1439

Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930 – 942

Elling D, Kroeker J, Kümmel S, Blohmer J, Lichtenegger W, Kohls A, Heinrich J, Quass J, Breitbach P, Kohler U (2000) Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4 – 9 positive lymph nodes. Zentralb Gynakol 122: 207 – 216

Fumoleau P, Kerbrat H, Romestaing P, Fargeot P, Bremond A, Namen M, Schraub S, Goudier MJ, Milhara J, Monnier A, Clavere P, Serin D, Seffert P, Fourny C, Facchini T, Jaccuin JP, Sztermier JF, Datchary J, Ramos R, Luporsi E (2003a) Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21: 298 – 305

Fumoleau P, Roché H, Kerbrat P, Bonnetterre J, Fargeot P, Namen M, Monnier A, Goudier M-J, Luporsi E, Chapelle-Marcillac I (2003b) Long-Term Benefit/Risk Ratio of Epirubicin (EPI)-Based Adjuvant Chemotherapy (CT) in Operable Breast Cancer (BC) Patients (pts): 7-Year Analysis in 3577 pts of French Adjuvant Study Group (FASG) trials, Chicago, IL: The American Society of Clinical Oncology, May 31 – June 3, 2003

Glück S (2001) The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer. Breast Cancer 8: 321 – 328

Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczkul KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei III E, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976 – 983

Hudis C, Citron M, Berry D, Cirrincione C, Gradishar W, Davidson N, Martino S, Livingston R, Ingle J, Perez E, Abrams J, Schilsky R, Ellis M, Carpenter J, Muss H, Norton L, Winer E, on behalf of CALG/ECOG/ SWOG/NCGCT Investigators (2005) Five year follow-up of INT C9741: dose-dense (DD) chemotherapy is safe and effective. San Antonio Breast Cancer Symposium, 11 December 2005, San Antonio, TX, USA; abstract 41 and unpublished presentation

Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnett M, Williams CK, Tu D (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651 – 2658

Link BK, Budd GT, Scott S, Dickman E, Paul D, Lawless G, Lee MW, Fridman M, Ford J, Carter WB (2001) Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92: 1354 – 1367

Lück HJ, Thomssen C, duBois A, Lisboa BW, Untch M, Kuhnle H, Konecny G, Janicke F, Meerpohl HG, Lindner C, Hacker D, Diergarten K (1996) Interim analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 23: 33 – 36

Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Forndenter T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure L, Hugh J, Loret C, Rupin M, Bliz S, Jacobs P, Murawsky M, Riva A, Vogel C (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302 – 2313

Möbus VJ, Untch M, Du Bois A, Lück HJ, Thomssen C, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C (2004) Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4+LN). First results of an AGO-trial. J Clin Oncol 22: 513

Oken MM, Creech RH, Torney DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649 – 655

Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18: 3558 – 3585

Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Analysis and examples. Br J Cancer 35: 1 – 39

Poole CJ, Earl HM, Dunn JA, Hiller L, Bathers S, Spooner D, Grieve R, Agrawall RK, Foster E, Twelves C (2003) Comparison of FEC100 vs 3 Cycles of FEC100 Followed by 3 Cycles of Docetaxel (D) for the Adjuvant Treatment of Node Positive Breast Cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, 8 – 11 December 2004

Sobin LH, Wittekind C, International Union against Cancer (1997) TNM Classification of Malignant Tumours. New York: John Wiley

Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E, Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253 – 1259